Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in Princeton, New Jersey and currently employs 107 full-time employees. The firm is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Follow-Up Questions
Quelle est la performance du prix de l'action YMAB ?
Le prix actuel de YMAB est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Y-mAbs Therapeutics Inc ?
Y-mAbs Therapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Y-mAbs Therapeutics Inc ?
La capitalisation boursière actuelle de Y-mAbs Therapeutics Inc est de $0
Est-ce que Y-mAbs Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 12 analystes ont établi des notations d'analystes pour Y-mAbs Therapeutics Inc, y compris 0 achat fort, 0 achat, 13 maintien, 1 vente et 0 vente forte
